New prospects in the management of functional reproductive disorders associated with polycystic ovary syndrome

Abstract

Polycystic ovary syndrome (PCOS) is the most common endocrinopathy in women of reproductive age associated with hyperandrogenism, anovulatory infertility and metabolic disorders. Along with hormonal therapy, reproductive disorders associated with polycystic ovary syndrome are managed with the help of drugs which increase insulin sensitivity, reduce secretion of insulin and androgens. A literature review demonstrated that myo-inositol, one of nine stereoisomers of hexa-hydroxy alcohol inositol, also helps to regulate the menstrual cycle, restore ovulation and maturation of oocytes, as well as reduces insulin resistance and hyperandrogenism. Myo-inositol seems to be promising in the treatment of PCOS and significantly improves IVF results.

Keywords

• синдром поликистозных яичников (спкя)
• инсулинорезистентность
• гиперинсулинемия
• терапия
• метформин
• polycystic ovary syndrome (pcos)
• insulin resistance
• hyperinsulinemia
• therapy
• metformin
• myo-inositol